A. M. Thirugnanam/LinkedIn
Sep 18, 2026, 15:01
A. M. Thirugnanam: Antiplatelet Discontinuation and the Risk of Stent Thrombosis
A. M. Thirugnanam, Senior Interventional Cardiologist at Kamineni Hospital, India, shared a post on LinkedIn:
“Premature antiplatelet discontinuation remains one of the most preventable causes of stent thrombosis, and it is very often triggered by well meaning advice from outside cardiology before a minor procedure.
Worth sharing with patients and with colleagues who schedule dental and endoscopic work.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH
-
Sep 18, 2026, 15:54Swapnil Pawar: Why Aren’t We Using Cryopreserved Platelets Everywhere Yet?
-
Sep 18, 2026, 15:37Abdul Mannan: Evaluating Longitudinal Platelet Trends Beyond Standard Reference Intervals
-
Sep 18, 2026, 15:30Peter A. Everts։ Platelet Phenotype May Hold the Key to More Consistent PRP Therapy
-
Sep 18, 2026, 15:25Brandon Temple: Turning Personal Experience Into Advocacy for wAIHA Research